Skip to search formSkip to main contentSkip to account menu

fotemustine

Known as: 1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester, diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate, diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate 
A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

Antineoplastic AgentsNitrosourea CompoundsOrganophosphorus Compounds

Narrower (2)

MuphoranS 10036
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Advances in therapy for melanoma brain metastases.
2007
2007
Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine
Background: Melanoma remains largely resistant to currently available chemotherapy, and new strategies have been proposed to… 
2004
2004
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine
SummaryTo date, dacarbazine (DTIC) has been the most effective drug in the treatment of advanced metastatic melanoma, achieving… 
2004
2004
Phase II trial of fotemustine in patients with metastatic malignant melanoma
SummaryFotemustine is a novel chloroethylnitrosourea, that readily penetrates the blood brain barrier. Preliminary French studies… 
1999
1999
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
BACKGROUND The DNA repair protein O6-alkylguanine-DNA alkyl transferase (AT) mediates resistance to chloroethylnitrosoureas… 
1998
1998
Modulation of O6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells.
Highly Cited
1997
Highly Cited
1997
Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Melanoma cells often display a multidrug-resistant phenotype, but the mechanisms involved are largely unknown. In order to… 
Highly Cited
1995
Highly Cited
1995
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group…
Fotemustine (FM) is a new chloronitrosurea (CNU), chemically characterized by the graft of an aminophosphonic acid on the CNU… 
1992
1992
Fotemustine — an advance in the treatment of metastatic malignant melanoma
Although chemotherapy has been generally of limited clinical benefit in the treatment of metastatic malignant melanoma (MMM… 
1991
1991
Liver targeting of autologous erythrocytes loaded with doxorubicin.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)